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Abstract
AIM: To investigate clinical and biochemical features of 
hepatorenal syndrome (HRS), to assess short and long-
term survival evaluating potential predictors of early 
mortality.
METHODS: Sixty-two patients with liver cirrhosis and 
renal failure, defined as a serum creatinine value > 
1.5 mg/dL on at least two measurements within 48 
h, admitted to our tertiary referral Unit from 2001 to 
201, were retrospectively reviewed. Among them, 33 
patients (53.2%) fulfilled the revised criteria of the 
International Ascites Club for the diagnosis of HRS. 
Twenty-eight patients were treated with combinations 
of terlipressin and albumin, two with dopamine and al-
bumin, and three with albumin alone. No patients were 
suitable for liver transplantation. Complete response 
was defined as normalization of creatinine levels to less 
than 1.5 mg/dL, partial response as a decrease of at 
least 50% but not to less than 1.5 mg/dL, no response 
as no reduction in creatinine or a decrease of less 50% 
compared to pre-treatment values. All of the patients 
were followed up for at least 1 year until January 2013.
RESULTS: HRS type 1 was diagnosed in 15 patients 
(45.5%). Hepatitis C virus  infection was the primary 
etiology (69.6%), followed by alcohol (15.2%), and 
cryptogenesis (15.2%). Complete response to therapy 
was obtained in only 3 cases (9.1%) and partial re-
sponse in 7 patients (21.2%). Median survival was 30 
d (range: 10-274) without significant differences be-
tween type 1 and type 2 HRS. By univariate analysis, 
Child-Pugh class C (P  = 0.009), presence of hepatocel-
lular carcinoma (P  = 0.04), low serum sodium (P  = 
0.02), high bilirubin values (P  = 0.009) and high Model 
for End-stage Liver Disease (MELD) score (P  = 0.03) 
were predictive factors of 30-d mortality. By multivari-
ate analysis, only serum sodium < 132 mEq/L (OR = 
31.39; P  = 0.02) and MELD score > 27 (OR = 18.72; P  
= 0.01) were independently associated with a survival 
of less than one month.
CONCLUSION: HRS still has a poor prognosis, even 
when vasoactive drug therapies are extensively used. 
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: Hepatorenal syndrome (HRS) is a life-threat-
ening complication of advanced liver disease. The aims 
of this study were to investigate the clinical and bio-
chemical features of HRS, to assess short- and long-
term survival, and to evaluate the presence of potential 
predictors of early mortality. Thirty-three patients with 
Online Submissions: http://www.wjgnet.com/esps/
bpgoffice@wjgnet.com
doi:10.4254/wjh.v5.i12.685
World J Hepatol  2013 December 27; 5(12): 685-691
ISSN 1948-5182 (online)
© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
685 December 27, 2013|Volume 5|Issue 12|WJH|www.wjgnet.com
Licata A et al . Clinical course and prognosis of HRS
liver cirrhosis and HRS were retrospectively reviewed. 
Median survival was 30 d. By univariate analysis Child-
Pugh class C, hepatocellular carcinoma, low serum so-
dium, high bilirubin and high Model for End-stage Liver 
Disease (MELD) score were predictive factors of 30-d 
mortality. By multivariate analysis, only serum sodium 
< 132 mEq/L and MELD score > 27 were independently 
associated with survival of less than one month.
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INTRODUCTION
Hepatorenal syndrome (HRS) is a life-threatening com-
plication of  advanced liver cirrhosis. It is characterized 
by functional renal failure, which develops as a result 
of  portal hypertension, splanchnic vasodilatation and 
consequential deterioration of  all systemic circulatory 
function[1]. Its incidence is approximately 8% per year in 
cirrhotic patients with ascites, but its incidence is greater 
in patients with advanced Child-Pugh scores[2]. The devel-
opment of  portal hypertension is associated with vascular 
arterial vasodilation in the splanchnic district, as a result 
of  increased local production of  nitric oxide and other 
vasodilators[3]. In the early stages of  liver cirrhosis, the re-
duction of  vascular resistance is compensated for by the 
development of  hyperdynamic circulation, characterized 
by increased cardiac output and heart rate[4]. HRS usually 
develops during the terminal stages of  liver disease, as 
soon as the hyperdynamic circulation is no longer able 
to compensate for the relative hypovolemia caused by 
splanchnic storage of  blood[5].
Some recent studies have shown a marked reduction 
of  cardiac output in patients with cirrhosis and HRS, 
in comparison to patients with cirrhosis without HRS, 
thus reappraising reduction in cardiac function as an im-
portant cofactor in the pathogenesis of  HRS[6,7]. Several 
lines of  evidence have finally proved that the results of  
systemic vasoconstriction can also cause significant hy-
poperfusion in other organs, such as the skin, muscles, 
brain and the liver itself. HRS can therefore be better 
considered a complex syndrome with systemic involve-
ment[8].
There are two well-recognized types of  HRS[9]. Type-1 
HRS is characterized by rapid progression of  renal fail-
ure, with doubling of  serum creatinine values to greater 
than 2.5 mg/dL in less than 2 wk. It is often triggered by 
a precipitating event, mainly bacterial infections, and it is 
associated with rapid deterioration of  circulatory status, 
with arterial hypotension and multiorgan failure. Type-1 
HRS has a poor prognosis, with median survival of  
only 2 wk, and its main consequence is represented by 
hepato-renal failure and death. In contrast, type-2 HRS 
is characterized by gradual renal failure, with a moder-
ate increase in serum creatinine to between 1.5 and 2.5 
mg/dL. It represents the natural functional renal failure 
that develops in patients with End-stage Liver Disease, 
as a result of  the natural history of  portal hypertension, 
and it often does not recognize a specific trigger. Type-2 
HRS has a better prognosis compared to type-1, with a 
median survival of  6 mo, and its principal consequence 
is represented by refractory ascites[10].
According to the European Association for the 
Study of  the Liver (EASL) Clinical Practice Guidelines, 
pharmacological therapy with terlipressin plus albumin 
should be considered as the first-line therapy[11]. How-
ever, the prognosis remains poor even when pharmaco-
logical therapy is extensively used, and orthotopic liver 
transplant (OLT) remains the best treatment for HRS. 
The aims of  our study were to investigate the clinical 
and biochemical features of  HRS, to assess short-term 
and long-term survival, and to evaluate potential predic-
tors of  early mortality.
MATERIALS AND METHODS
All patients with liver cirrhosis and renal failure, defined 
as a serum creatinine value > 1.5 mg/dL on at least two 
measurements within 48 h, admitted to our tertiary refer-
ral unit from 2001 to 2012, were retrospectively reviewed. 
Among them, we selected those who fulfilled the revised 
criteria of  the International Ascites Club for the diagno-
sis of  HRS[12]. The criteria were: (1) cirrhosis with ascites; 
(2) serum creatinine > 1.5 mg/dL; (3) no improvement in 
serum creatinine (decrease to a level < 1.5 mg/dL) after 
two days of  diuretics withdrawal and volume expansion 
with albumin (1 g/kg of  body weight up to a maximum 
of  100 g/d); (4) absence of  shock; (5) no current or re-
cent treatment with nephrotoxic drugs; and (6) absence 
of  parenchymal kidney disease, as indicated by a urinary 
protein concentration < 500 mg/d, a urinary red blood 
cell count < 50 cells per high power field, and normal 
renal ultrasonography. Type-1 HRS was defined by a 
large and rapid increase in serum creatinine to final val-
ues greater than 2.5 within 2 wk, while type-2 HRS was 
defined by a slower and more moderate increase in serum 
creatinine. The following were considered precipitating 
factors for type-1 HRS: spontaneous bacterial peritonitis 
and other infections diagnosed by standard methods; 
gastrointestinal bleeding; acute hepatitis superimposed on 
cirrhosis; and major surgical procedures.
Terlipressin was administered at a starting dose of  
between 0.5 and 1 mg every 4 h, increased to a maximum 
dose of  2 mg every 4 h if  there was no reduction in serum 
creatinine compared to the baseline value by day 3 of  thera-
py. Albumin was administered at an average dose of  40 g/d.
All of  the patients were followed up for at least 1 
year until January 2013. No patients were suitable for 
liver transplantation. Complete response was defined as 
normalization of  creatinine levels to less than 1.5 mg/dL, 
partial response as a decrease of  at least 50% but not to less 
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than 1.5 mg/dL, and no response as no reduction in creati-
nine or a decrease of  less 50% compared to pre-treatment 
values.
Statistical analysis
The results are reported as frequencies, medians or 
means and standard deviations. Student’s t-test, the 
Mann-Whitney and the (χ2 test were used to compare 
continuous or categorical variables. Multivariate analysis, 
including all of  the significant baseline variables (p < 
0.05), was also performed, using binary logistic regres-
sion to identify independent predictors of  outcomes. For 
this analysis, continuous variables were categorized using 
receiver operating characteristic curves. Survival analysis 
was conducted using the Kaplan-Meier method. The log-
rank test was used to compare survival between type-1 
and type-2 HRS. All of  the statistical analysis was per-
formed using SPSS software, version 20.0 for Macintosh 
(SPSS Inc., Chicago, IL, United States).
RESULTS
Among 62 patients with liver cirrhosis and acute renal 
failure, 33 patients (53.2%) fulfilled the revised criteria 
of  the International Ascites Club for the diagnosis of  
HRS[12]. The main clinical and laboratory characteristics 
are summarized in Tables 1 and 2. The mean age of  the 
patients was 65.9 years old (range: 39-83), with a compa-
rable sex distribution. Chronic hepatitis C virus infection 
was the main etiology, and approximately one third of  
patients were affected by hepatocellular carcinoma (HCC). 
Type-1 HRS was diagnosed in 15 patients (45.5%). 
Twenty-eight patients (84.8%) were treated with ter-
lipressin plus albumin, 2 patients (6.1%) with dopamine 
and albumin, and 3 patients (9.1%) with albumin alone. 
The median duration of  therapy was 7 d (range: 3-14). 
All of  the patients with partial or no response discontin-
ued treatment within 14 d. No significant adverse events 
occurred during vasoactive therapy. At the end of  treat-
ment, a complete response was obtained in 3 cases (9.1%), 
one with type-1 and two with type-2 HRS, and partial 
response was obtained in 7 patients (21.2%), four with 
type-1 and three with type-2 HRS.
The overall median survival was 30 d (range: 10-274) 
(Figure 1) without significant differences between type-1 
and type-2 HRS (p = 0.2 by log-rank test) (Figure 2). 
Between the two groups of  type-1 and type-2 HRS pa-
tients, there were no statistically significant differences 
except for serum creatinine, creatinine clearance, inter-
national normalized ratio (INR) values and End-stage 
Liver Disease (MELD) score (Table 3) (Figure 3).
Comparing the two groups of  patients according to 
30-d mortality, the variables associated with poorer prog-
nosis were Child-Pugh class C (p = 0.009), presence of  
HCC (p = 0.04), low serum sodium (p = 0.02), high bili-
rubin values (p = 0.009) and high MELD score (p = 0.03) 
(Table 4). By multivariate analysis, only serum sodium < 
132 mEq/L (OR = 31.39; p = 0.02) and MELD score 
> 27 (OR = 18.72; p = 0.01) were independently associ-
ated with survival of  less than one month (Table 5).
DISCUSSION
HRS is a life-threatening complication in patients with 
advanced liver cirrhosis, and it should always be distin-
guished from other causes of  renal failure. It is not always 
easy to recognize because there are no specific clinical or 
laboratory parameters that clearly allow for its diagnosis, 
so diagnosis is mainly based on the exclusion of  other 
causes of  renal failure. Currently, the new criteria of  the 
International Ascites Club are regarded as the gold stan-
dard for HRS diagnosis[12]. Nonetheless, a recent study by 
Salerno et al[13] showed that these criteria allow for a cor-
rect diagnosis in only two thirds of  cases.
According to the EASL Clinical Practice Guidelines, 
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  Age (yr), (mean ± SD) 65.9 ± 9.6 
  Sex
     Male 17 (51.5) 
     Female 16 (48.5) 
  Etiology
     HCV 23 (69.6)
     Alcohol   5 (15.2)
     Cryptogenic   5 (15.2)
  Child-Pugh
     B 18 (54.5)
     C 15 (45.5)
  Esophageal varices
     Absent   4 (14.3)
     F1 17 (60.7)
     F2   7 (25.0)
  Diabetes mellitus 13 (39.4)
  Hepatocellular carcinoma 12 (36.4)
  Portal Vein Thrombosis   7 (21.2)
  HRS
     Type-1 15 (45.5)
     Type-2 18 (54.5)
Table 1  Demographic and clinical features of 33 patients 
with hepatorenal syndrome  n  (%)
  Hemoglobin (g/dL) 10.3 ± 2.2
  White blood cells (× 103/mmc)   8.5 ± 5.7
  Platelets (× 103/mmc) 104.8 ± 85.2
  BUN (mg/dL) 145.17 ± 61.82
  Creatinine (mg/dL)   3.29 ± 1.09
  Creatinine clearance 19 (8-25.25)
  Sodium (mEq/L) 130.7 ± 5.5
  Potassium (mEq/L)     4.94 ± 0.85
  Urinary sodium (mEq/L) 6.5 (2-14) 
  Urinary potassium (mEq/L) 17.5 (11-29)
  Total bilirubin (mg/dL)       3.63 (1.63-13.2) 
  INR     1.47 (1.2-1.62) 
  MELD score    26 (22-32) 
Table 2  Laboratory features of patients with hepatorenal 
syndrome at diagnosis 
HRS: Hepatorenal syndrome; HCV: Hepatitis C virus.
Data are expressed as absolute mean ± SD or median (IQR). IQR: Interquar-
tile range; INR: International normalized ratio; BUN: Blood urea nitrogen; INR: 
International normalized ratio; MELD: Model for End stage liver disease.
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pharmacological therapy with terlipressin plus albumin 
should be considered the first-line therapy[11], even if  
terlipressin is not available in some countries, such as in 
the United States, and where it is available, there is not 
a standardized dose, due to the absence of  dose-finding 
studies. However, prognosis remains poor even when 
pharmacological therapy is extensively used, and OLT 
remains the best treatment for both type-1 and type-2 
HRS.
In our cohort, the prevalence of  HRS among pa-
tients with liver cirrhosis and renal failure was 53.2%, 
similar to the incidences found by Salerno et al[13] (45.8%) 
and Martín-Llahí et al[14] (43%). However, in contrast to 
above-cited studies, we found an equal prevalence of  
type-1 and type-2 HRS (45.5% vs 54.5%, respectively). 
This difference might have been due to the small sample 
size and to the elevated number of  patients with end-
stage cirrhosis who are followed in our Unit, who tend 
to develop mainly type-2 HRS.
Comparing type-1 and type-2 HRS patients, there 
were no statistically significant differences between the 
two groups, except for serum creatinine, creatinine clear-
ance, INR values and MELD score. Similarly, we found 
no differences in survival at 30 d between the groups. 
A difference in favor of  patients with type-2 HRS was 
observed over 30 d, but the number of  patients with 
survival longer than 30 d was very low, and the differ-
ence was not significant. Interestingly, we observed a 
poor rate of  response to vasoactive therapy, although 
this drug was administered at effective doses and for an 
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Figure 1  Overall survival of 33 patients with hepatorenal syndrome.
Figure 2  Overall survival of patients according to type-1 and type-2 hepa-
torenal syndrome (P = 0.2 by Log-rank test). HRS: Hepatorenal syndrome.
Figure 3  Box plot of distribution of model for end-stage liver disease 
scores in patients with type-1 and type-2 hepatorenal syndrome at diag-
nosis. HRS: Hepatorenal syndrome; MELD: Model for end stage liver disease.
Type-1 HRS
(n = 15)
Type-2 HRS
(n = 18)
P  value
  Age (yr) 63.3 ± 8.5 68.2 ± 10.2 0.150
  Sex
     Male 8 (53.3)   9 (50.0) 0.800
     Female 7 (46.7)   9 (50.0)
  Etiology 
     HCV 9 (60.0) 14 (77.8) 0.500
     Alcohol 3 (20.0)   2 (11.1)
     Cryptogenic 3 (20.0)   2 (11.1)
  Child-Pugh
     B 8 (53.3) 10 (55.6) 0.900
     C 7 (46.7)   8 (44.4)
  Diabetes mellitus 5 (33.3)   8 (44.4) 0.500
  Hepatocellular carcinoma 6 (40.0)   6 (33.3) 0.700
  Portal vein thrombosis 4 (26.7)   3 (16.7) 0.500
  Platelets (× 103/mmc) 108.7 ± 96.6  101.6 ± 7711 0.800
  BUN (mg/dL)    152 ± 73.4      139.5 ± 51.7 0.500
  Creatinine (mg/dL)   3.95 ± 1.13   2.75 ± 0.71 0.001
  Creatinine clearance 8 (5.2-17) 24.5 (15-26) 0.030
  Sodium (mEq/L) 130.8 ± 4.24 130.7 ± 6.47 0.900
  Potassium (mEq/L)     4.9 ± 0.96   4.97 ± 0.78 0.800
  Urinary sodium (mEq/L)    11 (2.0-17.7)         6 (2-11) 0.700
  Urinary potassium (mEq/L)    19 (7.2-38.2)      16 (11-27.75) 0.900
  Total bilirubin (mg/dL) 6.37 (1.6-27.1)  2.62 (1.3-13.2) 0.200
  INR 1.51 (1.3-2.2)  1.29 (1.18-1.6) 0.040
  MELD score    31 (26-33) 23 (20-26) 0.010
Table 3  Comparison between type-1 and type-2 hepatorenal 
syndrome 
Data are expressed as absolute mean ± SD or median (IQR). IQR: Inter-
quartile range; BUN: Blood urea nitrogen; INR: International normalized 
ratio; MELD: Model for End stage liver disease.
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adequate period of  time. In particular, a response was 
observed in only 30.3% of  cases (complete response: 
9.1%; partial response: 21.2%). These results were lower 
compared to those observed in the literature[15-21]. In a re-
cent study, Salerno et al[13] achieved a response in 50% of  
cases, with a higher percentage of  complete than partial 
response (30% vs 20%, respectively). This finding might 
be secondary to the differences between the patients in 
our cohort and those recruited for prospective studies, 
particularly for randomized controlled trials. In addition, 
the numbers of  patients with hepatocellular carcinoma 
and with portal vein thrombosis were not specified in 
Salerno and colleagues’ paper; however, patients with ad-
vanced HCC and advanced cirrhosis did not receive any 
treatment. In our cohort, 36.4% of  patients had HCC, 
most of  whom were in advanced stages, and 21.2% had 
a portal vein thrombosis, none of  whom were suitable 
for liver transplantation. Consequently, we likely ob-
tained a worse response to therapy because of  the worse 
pre-treatment prognosis of  our patients.
Comparing the two groups of  patients with survival 
shorter and longer than 30 d, Child-Pugh class C, pres-
ence of  HCC, low serum sodium, high bilirubin values 
and high MELD scores were associated with lower sur-
vival (Table 4). By multivariate analysis, only serum so-
dium less than 132 mEq/L, and MELD score greater than 
27 were independently associated with 30-d mortality.
Overall, these results confirm that prognosis was 
negatively influenced by the severe impairment of  liver 
function, highlighting the role of  MELD score as a 
prognostic factor in patients with cirrhosis and renal fail-
ure, as already described in other studies[22-24].
This study had several limitations. First, the sample 
size was small. Second, there were a relatively large 
number of  patients with co-morbidities that adversely 
affected the prognosis, such as hepatocellular carcinoma, 
as confirmed by the ineligibility of  any patients for OLT. 
Third, none of  the patients included were treated with a 
combination of  midodrine and octreotide. This combi-
nation would have been useful to compare the outcomes 
of  patients treated with terlipressin to those treated with 
midodrine and octreotide. Finally, none of  the patients 
underwent liver transplantation, so we were not able to 
evaluate the impact of  vasoactive therapy as a bridge to 
OLT in our cohort.
HRS still has a poor prognosis, even when drug ther-
apy is extensively used. The impact of  vasoactive drugs 
is poor, and the true effectiveness of  these drugs is in 
prolonging short-term survival, as a bridge to transplan-
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< 30-d 
mortality
(n  = 16)
≥ 30-d 
mortality
(n = 17)
P  value
  Age (yr) 62.9 ± 11.4 68.7 ± 6.6 0.080
  Sex
  Male 8 (50.0)   9 (52.9) 0.800
     Female 8 (50.0)   8 (47.1)
     Etiology 
     HCV 10 (62.5) 13 (76.5) 0.600
     Alcohol   3 (18.8)   2 (11.8)
     Cryptogenic   3 (18.8)   2 (11.8)
  Child-Pugh
     B   5 (31.3) 13 (76.5) 0.009
     C 11 (68.8)   4 (23.5)
  Esophageal varices
     Absent   2 (14.3)   2 (14.3) 0.900
     F1   8 (57.1)   9 (64.3)
     F2   4 (28.6)   3 (21.4)
  Diabetes mellitus   6 (37.5)   7 (41.2) 0.800
  Hepatocellular carcinoma   3 (18.8)   9 (52.9) 0.040
  Portal vein thrombosis   2 (12.5)   5 (29.4) 0.200
  Platelets (× 103/mmc) 103.4 ± 87.9  106.1 ± 85.2 0.900
  BUN (mg/dL) 134.8 ± 40.5  154.8 ± 76.8 0.300
  Creatinine (mg/dL) 3.14 ± 0.8    3.44 ± 1.32 0.400
  Creatinine clearance    26 (20-37) 13 (8-24) 0.050
  Sodium (mEq/L) 128.5 ± 4.6 132.8 ± 5.5 0.020
  Potassium (mEq/L)     4.77 ± 0.87       5.1 ± 0.82 0.200
  Urinary sodium (mEq/L)  11 (7-18) 4 (2-13) 0.200
  Urinary potassium (mEq/L)     25 (19-29) 15 (10-27) 0.200
  Total bilirubin (mg/dL)     10.8 (3.2-21.2)   1.8 (1.5 - 3.6) 0.009
  INR     1.6 (1.3-1.7)  1.2 (1.2-1.5) 0.560
  MELD score        31 (26-33) 23 (20-26) 0.030
  HRS
     Type-1          8 (50)  7 (41.2) 0.600
     Type-2          8 (50) 10 (58.8)
Table 4  Comparison of patients according to 30-d mortality
  Variable < 30-d 
mortality
n  (%)
≥ 30-d 
mortality
n  (%)
Crude OR
(95%CI)
Adjusted 
OR
(95%CI)
P value
  Age, (yr)
     < 65 7 (43.8)   4 (23.5) 1 -
     ≥ 65 9 (56.2) 13 (76.5) 2.53 
(0.57-11.26)
  Child-Pugh class
     B   5 (31.2) 13 (76.5) 1 11.98 
(0.97-148.23)
0.053
     C 11 (68.8)   4 (23.5) 7.15 
(1.53-33.37)
  Sodium 
     ≥ 132 mEq/L   3 (18.8) 10 (58.8) 1
     < 132 mEq/L 13 (81.2)   7 (41.2) 6.19 
(1.27-30.17)
31.39 
(1.54-641.83)
0.020
  Total bilirubin
     ≤ 3.6 mg/dL   4 (25.0) 12 (70.6) 1
     > 3.6 mg/dL 12 (75.0)   5 (29.4) 7.20 
(1.55-33.56)
0.69 
(0.17-28.06)
0.800
  Hepatocellular carcinoma
     Absent
     Present 13 (81.2)   8 (47.1) 1
  3 (18.8)   9 (52.9) 4.88 
(1.01-23.57)
1.37 
(0.13-14.91)
0.700
  MELD score
     ≤ 27   4 (25.0) 14 (82.4) 1
     > 27 12 (75.0)   3 (17.6) 14.0 
(2.60-75.41)
18.72 
(1.63-214.56)
0.010
Table 5  Risk factors associated with 30-d mortality in pa-
tients with hepatorenal syndrome 
Data are expressed as absolute n (%), mean ± SD or median (IQR). IQR: 
Interquartile range; BUN: Blood urea nitrogen; INR: International normal-
ized ratio; MELD: Model for End stage liver disease; HRS: Hepatorenal 
syndrome.
Crude and adjusted odds ratio (OR) deriving from multiple logistic regres-
sion analysis. CI: Confidence interval; MELD: Model for End stage liver 
disease.
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tation, in patients suitable for OLT. In this setting, the 
use of  TIPS has been limited by the absence of  large, 
prospective studies and by restricted use in patients with 
end-stage cirrhosis[25,26]. Prognostic factors for short-
term mortality (low serum sodium and high MELD 
score) could be used to choose candidate patients for 
OLT as soon as possible after the onset of  HRS.
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